Search

Your search keyword '"Saida, Satoshi"' showing total 280 results
Start Over Author "Saida, Satoshi"
280 results on '"Saida, Satoshi"'

1. Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms

Author

Sato, Tomohiko, Yoshida, Kenichi, Toki, Tsutomu, Kanezaki, Rika, Terui, Kiminori, Saiki, Ryunosuke, Ojima, Masami, Ochi, Yotaro, Mizuno, Seiya, Yoshihara, Masaharu, Uechi, Tamayo, Kenmochi, Naoya, Tanaka, Shiro, Matsubayashi, Jun, Kisai, Kenta, Kudo, Ko, Yuzawa, Kentaro, Takahashi, Yuka, Tanaka, Tatsuhiko, Yamamoto, Yohei, Kobayashi, Akie, Kamio, Takuya, Sasaki, Shinya, Shiraishi, Yuichi, Chiba, Kenichi, Tanaka, Hiroko, Muramatsu, Hideki, Hama, Asahito, Hasegawa, Daisuke, Sato, Atsushi, Koh, Katsuyoshi, Karakawa, Shuhei, Kobayashi, Masao, Hara, Junichi, Taneyama, Yuichi, Imai, Chihaya, Hasegawa, Daiichiro, Fujita, Naoto, Yoshitomi, Masahiro, Iwamoto, Shotaro, Yamato, Genki, Saida, Satoshi, Kiyokawa, Nobutaka, Deguchi, Takao, Ito, Masafumi, Matsuo, Hidemasa, Adachi, Souichi, Hayashi, Yasuhide, Taga, Takashi, Saito, Akiko M., Horibe, Keizo, Watanabe, Kenichiro, Tomizawa, Daisuke, Miyano, Satoru, Takahashi, Satoru, Ogawa, Seishi, and Ito, Etsuro

Published
2024
Full Text
View/download PDF

3. MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma.

Author

Uchihara, Yoshinori, Umeda, Katsutsugu, Yamada, Yosuke, Ito, Hiroaki, Tasaka, Keiji, Isobe, Kiyotaka, Akazawa, Ryo, Kawabata, Naoko, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Noguchi, Takashi, Sakamoto, Akio, Arakawa, Yoshiki, Arakawa, Ayumu, Yamamoto, Nobuyuki, Hosoya, Yosuke, Uemura, Suguru, Watanabe, Ken‐ichiro, and Sano, Hideki

Abstract

The prognosis of patients with osteosarcoma who experience recurrence or progression (R/P) is extremely poor, and more effective and less toxic therapies are needed. In the current study, the clinical data of osteosarcoma patients who experienced R/P were retrospectively analyzed to verify the reliability of O‐6‐methylguanine‐DNA methyltransferase (MGMT) protein expression or MGMT promoter methylation for predicting the response to off‐label temozolomide (TMZ)‐containing chemotherapy. Of the 30 evaluable patients, 9 (30%) showed no/low MGMT protein expression, whereas all 16 evaluable patients had unmethylated MGMT promoter irrespective of MGMT protein expression levels. Twenty‐three patients received TMZ‐containing chemotherapy for measurable lesions (n = 14) or as adjuvant therapy following resection of recurrent lesions (n = 9). Among 14 patients with radiologically measurable lesions, the objective response rate was higher in the MGMT no/low‐expression group (50.0%) than in the MGMT intermediate/high‐expression group with borderline significance (0%, p = 0.066). The 6‐month progression‐free survival (PFS) rate in patients with radiologically measurable lesions was significantly higher in the MGMT no/low‐expression group (50.0%) than in the MGMT intermediate/high‐expression group (0%, p = 0.036). In the multivariate analysis of the 23 patients receiving TMZ‐containing chemotherapy, MGMT expression and disease status before TMZ‐containing chemotherapy were significantly associated with PFS. No severe adverse effects were observed during TMZ‐containing chemotherapy. MGMT protein expression, but not MGMT promoter methylation, could predict a favorable outcome in patients receiving TMZ‐containing chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia

Author

Kubota, Hirohito, primary, Ueno, Hiroo, additional, Tasaka, Keiji, additional, Isobe, Tomoya, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Umeda, Katsutsugu, additional, Hiwatari, Mitsuteru, additional, Hasegawa, Daiichiro, additional, Imamura, Toshihiko, additional, Kakiuchi, Nobuyuki, additional, Nannya, Yasuhito, additional, Ogawa, Seishi, additional, Hiramatsu, Hidefumi, additional, and Takita, Junko, additional

Published
2023
Full Text
View/download PDF

8. Author Correction: Pluripotent stem cell model of Shwachman–Diamond syndrome reveals apoptotic predisposition of hemoangiogenic progenitors

Author

Hamabata, Takayuki, Umeda, Katsutsugu, Kouzuki, Kagehiro, Tanaka, Takayuki, Daifu, Tomoo, Nodomi, Seishiro, Saida, Satoshi, Kato, Itaru, Baba, Shiro, Hiramatsu, Hidefumi, Osawa, Mitsujiro, Niwa, Akira, Saito, Megumu K., Kamikubo, Yasuhiko, Adachi, Souichi, Hashii, Yoshiko, Shimada, Akira, Watanabe, Hiroyoshi, Osafune, Kenji, Okita, Keisuke, Nakahata, Tatsutoshi, Watanabe, Kenichiro, Takita, Junko, and Heike, Toshio

Published
2021
Full Text
View/download PDF

10. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy

Author

Jo, Tomoyasu, Yoshihara, Satoshi, Hada, Asuka, Arai, Yasuyuki, Kitawaki, Toshio, Ikemoto, Junko, Onomoto, Hitomi, Sugiyama, Hiroki, Yoshihara, Kyoko, Obi, Natsuno, Matsui, Keiko, Niwa, Norimi, Nakagawa, Yoko, Kanda, Junya, Kondo, Tadakazu, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Adachi, Souichi, Takita, Junko, Takaori-Kondo, Akifumi, and Nagao, Miki

Published
2022
Full Text
View/download PDF

13. Pluripotent stem cell model of Shwachman–Diamond syndrome reveals apoptotic predisposition of hemoangiogenic progenitors

Author

Hamabata, Takayuki, Umeda, Katsutsugu, Kouzuki, Kagehiro, Tanaka, Takayuki, Daifu, Tomoo, Nodomi, Seishiro, Saida, Satoshi, Kato, Itaru, Baba, Shiro, Hiramatsu, Hidefumi, Osawa, Mitsujiro, Niwa, Akira, Saito, Megumu K., Kamikubo, Yasuhiko, Adachi, Souichi, Hashii, Yoshiko, Shimada, Akira, Watanabe, Hiroyoshi, Osafune, Kenji, Okita, Keisuke, Nakahata, Tatsutoshi, Watanabe, Kenichiro, Takita, Junko, and Heike, Toshio

Published
2020
Full Text
View/download PDF

15. Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura

Author

Shino, Yuki, primary, Umeda, Katsutsugu, additional, Uchihara, Yoshinori, additional, Mitani, Kazuki, additional, Tasaka, Keiji, additional, Ogata, Hideto, additional, Kobushi, Hirokazu, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Yoshida, Takeshi, additional, Yokoyama, Atsushi, additional, Hiramatsu, Hidefumi, additional, and Takita, Junko, additional

Published
2023
Full Text
View/download PDF

16. Successful sequential therapy with rituximab and daratumumab for refractory post-transplant immune thrombocytopenic purpura

Author

Umeda, Katsutsugu, primary, Shino, Yuki, additional, Uchihara, Yoshinori, additional, Mitani, Kazuki, additional, Tasaka, Keiji, additional, Ogata, Hideto, additional, Kobushi, Hirokazu, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Yoshida, Takeshi, additional, Yokoyama, Atsushi, additional, Hiramatsu, Hidefumi, additional, and Takita, Junko, additional

Published
2023
Full Text
View/download PDF

17. High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma

Author

Kobushi, Hirokazu, primary, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Iwai, Atsushi, additional, Kozuki, Kagehiro, additional, Kubota, Hirohito, additional, Tanaka, Kuniaki, additional, Obu, Satoshi, additional, Uchihara, Yoshinori, additional, Tasaka, Keiji, additional, Kato, Itaru, additional, Hiramatsu, Hidefumi, additional, and Takita, Junko, additional

Published
2023
Full Text
View/download PDF

18. Data from Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia

Author

Nemoto, Atsushi, primary, Saida, Satoshi, primary, Kato, Itaru, primary, Kikuchi, Jiro, primary, Furukawa, Yusuke, primary, Maeda, Yasuhiro, primary, Akahane, Koshi, primary, Honna-Oshiro, Hiroko, primary, Goi, Kumiko, primary, Kagami, Keiko, primary, Kimura, Shinya, primary, Sato, Yuko, primary, Okabe, Seiichi, primary, Niwa, Akira, primary, Watanabe, Kenichiro, primary, Nakahata, Tatsutoshi, primary, Heike, Toshio, primary, Sugita, Kanji, primary, and Inukai, Takeshi, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure from Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia

Author

Nemoto, Atsushi, primary, Saida, Satoshi, primary, Kato, Itaru, primary, Kikuchi, Jiro, primary, Furukawa, Yusuke, primary, Maeda, Yasuhiro, primary, Akahane, Koshi, primary, Honna-Oshiro, Hiroko, primary, Goi, Kumiko, primary, Kagami, Keiko, primary, Kimura, Shinya, primary, Sato, Yuko, primary, Okabe, Seiichi, primary, Niwa, Akira, primary, Watanabe, Kenichiro, primary, Nakahata, Tatsutoshi, primary, Heike, Toshio, primary, Sugita, Kanji, primary, and Inukai, Takeshi, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table from Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia

Author

Nemoto, Atsushi, primary, Saida, Satoshi, primary, Kato, Itaru, primary, Kikuchi, Jiro, primary, Furukawa, Yusuke, primary, Maeda, Yasuhiro, primary, Akahane, Koshi, primary, Honna-Oshiro, Hiroko, primary, Goi, Kumiko, primary, Kagami, Keiko, primary, Kimura, Shinya, primary, Sato, Yuko, primary, Okabe, Seiichi, primary, Niwa, Akira, primary, Watanabe, Kenichiro, primary, Nakahata, Tatsutoshi, primary, Heike, Toshio, primary, Sugita, Kanji, primary, and Inukai, Takeshi, primary

Published
2023
Full Text
View/download PDF

21. Clinical Outcomes of Patients with Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience

Author

80397538, 40335964, 70638254, 10610454, 40362503, 20826028, 90314210, 10252462, 60252962, 00359621, Umeda, Katsutsugu, Sakamoto, Akio, Noguchi, Takashi, Uchihara, Yoshinori, Kobushi, Hirokazu, Akazawa, Ryo, Ogata, Hideto, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Uto, Megumi, Mizowaki, Takashi, Haga, Hironori, Date, Hiroshi, Okamoto, Takeshi, Watanabe, Kenichiro, Adachi, Souichi, Toguchida, Junya, Matsuda, Shuichi, Takita, Junko, 80397538, 40335964, 70638254, 10610454, 40362503, 20826028, 90314210, 10252462, 60252962, 00359621, Umeda, Katsutsugu, Sakamoto, Akio, Noguchi, Takashi, Uchihara, Yoshinori, Kobushi, Hirokazu, Akazawa, Ryo, Ogata, Hideto, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Uto, Megumi, Mizowaki, Takashi, Haga, Hironori, Date, Hiroshi, Okamoto, Takeshi, Watanabe, Kenichiro, Adachi, Souichi, Toguchida, Junya, Matsuda, Shuichi, and Takita, Junko

Abstract

[Background:] Patients with osteosarcoma who experience relapse or progression [R/P] have a poor prognosis. [Methods:] Data from 30 patients who experienced R/P among 59 with a diagnosis of high-grade osteosarcoma, who were younger than 40 years old between 2000 and 2019, were retrospectively analyzed to identify prognostic and therapeutic factors influencing their outcomes. [Results:] The 5-year overall survival [OS] rates after the last R/P of patients experiencing first [n=30], second [n=14], and third [n=9] R/P were 50.3%, 51.3%, and 46.7%, respectively. Multivariate analysis did not identify any independent risk factors affecting OS. The 5-year PFS rate of the 30 patients after first R/P was 22.4%, and multivariate analysis identified histologic subtype and curative local surgery as independent risk factors influencing PFS. Long [>6 mo] partial response was observed in three patients treated using temozolomide+etoposide, irinotecan+carboplatin, or regorafenib. [Conclusions:] OS rate in the patients with osteosarcoma experiencing R/P included in this study was markedly higher than that reported previously, mainly due to the surgical total removal of tumors, even after subsequent R/P. The recent establishment of salvage chemotherapy or molecular targeted therapy may also increase survival rates in a subgroup of patients.

Published
2023

22. Use of Cabozantinib to Treat MET-amplified Pediatric Colorectal Cancer

Author

80397538, 70638254, 10610454, 40362503, 00359621, Fukui, Sadahiro, Umeda, Katsutsugu, Kubota, Hirohito, Iwai, Atsushi, Akazawa, Ryo, Isobe, Kiyotaka, Tanaka, Kuniaki, Kouzuki, Kagehiro, Kawabata, Naoko, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Itatani, Yoshiro, Funakoshi, Taro, Adachi, Souichi, Takita, Junko, 80397538, 70638254, 10610454, 40362503, 00359621, Fukui, Sadahiro, Umeda, Katsutsugu, Kubota, Hirohito, Iwai, Atsushi, Akazawa, Ryo, Isobe, Kiyotaka, Tanaka, Kuniaki, Kouzuki, Kagehiro, Kawabata, Naoko, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Itatani, Yoshiro, Funakoshi, Taro, Adachi, Souichi, and Takita, Junko

Abstract

Pediatric colorectal cancer (CRC) is extremely rare, with little information about genetic profiles compared with adult CRC. Here, a 13-year-old male with advanced CRC underwent cancer gene panel testing, which detected 4 genetic abnormalities (MET amplification in addition to TP53, SMAD4, and CTNNA1 mutations) that might be associated with a poor prognosis. Based on high-level MET amplification, he received a multikinase inhibitor, cabozantinib, after failure of first-line and second-line chemotherapy, resulting in transient disease stabilization. Tailored targeted therapy based on molecular profiling can be an effective treatment strategy for rare cancers such as pediatric CRC.

Published
2023

23. A scalp dose threshold for preventing permanent alopecia in scalp-avoidance whole-brain irradiation with volumetric-modulated arc radiotherapy (SAWB-VMAT) for pediatric patients with medulloblastomas

Author

Torizuka, Daichi, primary, Uto, Megumi, additional, Umeda, Katsutsugu, additional, Kamitori, Tatsuya, additional, Iwai, Atsushi, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Mineharu, Yohei, additional, Arakawa, Yoshiki, additional, Takita, Junko, additional, and Mizowaki, Takashi, additional

Published
2023
Full Text
View/download PDF

24. Second relapse of FLT3 ‐ITD‐positive acute myeloid leukemia after discontinuation of 3‐year post‐transplant maintenance therapy with gilteritinib

Author

Tasaka, Keiji, primary, Kato, Itaru, additional, Takeshita, Shunki, additional, Yoshioka, Yu, additional, Usami, Ayuko, additional, Uchihara, Yoshinori, additional, Akazawa, Ryo, additional, Kamitori, Tatsuya, additional, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

25. Clinical utility of cerebrospinal fluid-placental alkaline phosphatase for the diagnosis of intracranial germinoma

Author

Obu, Satoshi, primary, Umeda, Katsutsugu, additional, Iwanaga, Kougoro, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Hiramatsu, Hidefumi, additional, Mineharu, Yohei, additional, Arakawa, Yoshiki, additional, Uto, Megumi, additional, Mizowaki, Takashi, additional, Adachi, Souichi, additional, Daifu, Tomoo, additional, Kawai, Masahiko, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

30. Autologous Recovery With Chromosomal Abnormalities After Unrelated Umbilical Cord Blood Transplantation With Myeloablative Conditioning in a Case of Pediatric Acute Lymphoblastic Leukemia

Author

Uchihara, Yoshinori, primary, Kato, Itaru, additional, Hanaki, Ryo, additional, Saida, Satoshi, additional, Iwamoto, Shotaro, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

33. Clinical Outcomes of Patients With Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience

Author

Umeda, Katsutsugu, primary, Sakamoto, Akio, additional, Noguchi, Takashi, additional, Uchihara, Yoshinori, additional, Kobushi, Hirokazu, additional, Akazawa, Ryo, additional, Ogata, Hideto, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Hiramatsu, Hidefumi, additional, Uto, Megumi, additional, Mizowaki, Takashi, additional, Haga, Hironori, additional, Date, Hiroshi, additional, Okamoto, Takeshi, additional, Watanabe, Kenichiro, additional, Adachi, Souichi, additional, Toguchida, Junya, additional, Matsuda, Shuichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

34. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome

Author

Saida, Satoshi, Watanabe, Ken-ichiro, Sato-Otsubo, Aiko, Terui, Kiminori, Yoshida, Kenichi, Okuno, Yusuke, Toki, Tsutomu, Wang, RuNan, Shiraishi, Yuichi, Miyano, Satoru, Kato, Itaru, Morishima, Tatsuya, Fujino, Hisanori, Umeda, Katsutsugu, Hiramatsu, Hidefumi, Adachi, Souichi, Ito, Etsuro, Ogawa, Seishi, Ito, Mamoru, Nakahata, Tatsutoshi, and Heike, Toshio

Published
2013
Full Text
View/download PDF

35. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch

Author

70992337, 10610454, 70638254, 80397538, 40362503, 00359621, Nakajima, Koji, Kubota, Hirohito, Kato, Itaru, Isobe, Kiyotaka, Ueno, Hiroo, Kozuki, Kagehiro, Tanaka, Kuniaki, Kawabata, Naoko, Mikami, Takashi, Tamefusa, Kosuke, Nishiuchi, Ritsuo, Saida, Satoshi, Umeda, Katsutsugu, Hiramatsu, Hidefumi, Adachi, Souichi, Takita, Junko, 70992337, 10610454, 70638254, 80397538, 40362503, 00359621, Nakajima, Koji, Kubota, Hirohito, Kato, Itaru, Isobe, Kiyotaka, Ueno, Hiroo, Kozuki, Kagehiro, Tanaka, Kuniaki, Kawabata, Naoko, Mikami, Takashi, Tamefusa, Kosuke, Nishiuchi, Ritsuo, Saida, Satoshi, Umeda, Katsutsugu, Hiramatsu, Hidefumi, Adachi, Souichi, and Takita, Junko

Abstract

Lineage switch is a rare event at leukemic relapse. While mostly known to occur in KMT2A-rearranged infant leukemia, the underlying mechanism is yet to be depicted. This case report describes a female infant who achieved remission of KMT2A-MLLT3-rearranged acute monocytic leukemia, but 6 months thereafter, relapsed as KMT2A-MLLT3-rearranged acute lymphocytic leukemia. Whole exome sequencing of the bone marrow obtained pre-post lineage switch revealed two somatic mutations of PAX5 in the relapse sample. These two PAX5 alterations were suggested to be loss of function, thus to have played the driver role in the lineage switch from acute monocytic leukemia to acute lymphocytic leukemia.

Published
2022

36. Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia

Author

10610454, 70638254, 80397538, 40362503, 00359621, Mikami, Takashi, Kato, Itaru, Wing, James Badger, Ueno, Hiroo, Tasaka, Keiji, Tanaka, Kuniaki, Kubota, Hirohito, Saida, Satoshi, Umeda, Katsutsugu, Hiramatsu, Hidefumi, Isobe, Tomoya, Hiwatari, Mitsuteru, Okada, Ai, Chiba, Kenichi, Shiraishi, Yuichi, Tanaka, Hiroko, Miyano, Satoru, Arakawa, Yuki, Oshima, Koichi, Koh, Katsuyoshi, Adachi, Souichi, Iwaisako, Keiko, Ogawa, Seishi, Sakaguchi, Shimon, Takita, Junko, 10610454, 70638254, 80397538, 40362503, 00359621, Mikami, Takashi, Kato, Itaru, Wing, James Badger, Ueno, Hiroo, Tasaka, Keiji, Tanaka, Kuniaki, Kubota, Hirohito, Saida, Satoshi, Umeda, Katsutsugu, Hiramatsu, Hidefumi, Isobe, Tomoya, Hiwatari, Mitsuteru, Okada, Ai, Chiba, Kenichi, Shiraishi, Yuichi, Tanaka, Hiroko, Miyano, Satoru, Arakawa, Yuki, Oshima, Koichi, Koh, Katsuyoshi, Adachi, Souichi, Iwaisako, Keiko, Ogawa, Seishi, Sakaguchi, Shimon, and Takita, Junko

Abstract

Due to the considerable success of cancer immunotherapy for leukemia, the tumor immune environment has become a focus of intense research; however, there are few reports on the dynamics of the tumor immune environment in leukemia. Here, we analyzed the tumor immune environment in pediatric B cell precursor acute lymphoblastic leukemia by analyzing serial bone marrow samples from nine patients with primary and recurrent disease by mass cytometry using 39 immunophenotype markers, and transcriptome analysis. High-dimensional single-cell mass cytometry analysis elucidated a dynamic shift of T cells from naïve to effector subsets, and clarified that, during relapse, the tumor immune environment comprised a T helper 1-polarized immune profile, together with an increased number of effector regulatory T cells. These results were confirmed in a validation cohort using conventional flow cytometry. Furthermore, RNA transcriptome analysis identified the upregulation of immune-related pathways in B cell precursor acute lymphoblastic leukemia cells during relapse, suggesting interaction with the surrounding environment. In conclusion, a tumor immune environment characterized by a T helper 1-polarized immune profile, with an increased number of effector regulatory T cells, could contribute to the pathophysiology of recurrent B cell precursor acute lymphoblastic leukemia. This information could contribute to the development of effective immunotherapeutic approaches against B cell precursor acute lymphoblastic leukemia relapse.

Published
2022

37. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy

Author

10826564, 50378684, 30636311, 10610454, 40362503, 00359621, 80523993, Jo, Tomoyasu, Yoshihara, Satoshi, Hada, Asuka, Arai, Yasuyuki, Kitawaki, Toshio, Ikemoto, Junko, Onomoto, Hitomi, Sugiyama, Hiroki, Yoshihara, Kyoko, Obi, Natsuno, Matsui, Keiko, Niwa, Norimi, Nakagawa, Yoko, Kanda, Junya, Kondo, Tadakazu, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Adachi, Souichi, Takita, Junko, Takaori-Kondo, Akifumi, Nagao, Miki, 10826564, 50378684, 30636311, 10610454, 40362503, 00359621, 80523993, Jo, Tomoyasu, Yoshihara, Satoshi, Hada, Asuka, Arai, Yasuyuki, Kitawaki, Toshio, Ikemoto, Junko, Onomoto, Hitomi, Sugiyama, Hiroki, Yoshihara, Kyoko, Obi, Natsuno, Matsui, Keiko, Niwa, Norimi, Nakagawa, Yoko, Kanda, Junya, Kondo, Tadakazu, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Adachi, Souichi, Takita, Junko, Takaori-Kondo, Akifumi, and Nagao, Miki

Abstract

As chimeric antigen receptor (CAR) T cell therapy targeting CD19 has shown favorable outcomes in patients with relapsed or refractory (r/r) mature B cell lymphomas and B cell acute lymphoblastic leukemia (B-ALL), an increasing number of patients are waiting to receive these treatments. Optimized protocols for T cell collection by lymphapheresis for chimeric antigen receptor (CAR) T cell therapy are urgently needed to provide CAR T cell therapy for patients with refractory and progressive disease and/or a low number of lymphocytes owing to prior chemotherapy. The predicted efficiency of CD³⁺ cell collection in apheresis can guide protocols for apheresis, but a clinically applicable model to produce reliable estimates has not yet been established. In this study, we prospectively analyzed 108 lymphapheresis procedures for tisagenlecleucel therapy at 2 centers. The apheresis procedures included 20 procedures in patients with B cell acute lymphoblastic leukemia and 88 procedures in patients with diffuse large B cell lymphoma, with a median age at apheresis of 58 years (range, 1 to 71 years). After lymphapheresis with a median processing blood volume of 10 L (range, 3 to 16 L), a median of 3.2 × 10⁹ CD³⁺ cells (range, .1 to 15.0 × 10⁹ cells) were harvested. Collection efficiency 2 (CE2) for CD³⁺ cells was highly variable (median, 59.3%; range, 11.0% to 199.8%). Multivariate analyses revealed that lower hemoglobin levels, higher circulating CD3+ cell counts, and higher platelet counts before apheresis significantly decreased apheresis CE2. Based on multivariate analyses, we developed a novel formula that estimates CE2 from precollection parameters with high accuracy (r = .56; P < .01), which also suggests the necessary processing blood volume. Our strategy for lymphapheresis should help reduce collection failure, as well as achieve efficient utilization of medical resources in clinical practice, thereby allowing delivery of CAR T cell therapy to more patients in a timely m

Published
2022

40. Clinical Outcomes of Patients With Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience.

Author

Umeda, Katsutsugu, Sakamoto, Akio, Noguchi, Takashi, Uchihara, Yoshinori, Kobushi, Hirokazu, Akazawa, Ryo, Ogata, Hideto, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Uto, Megumi, Mizowaki, Takashi, Haga, Hironori, Date, Hiroshi, Okamoto, Takeshi, Watanabe, Kenichiro, Adachi, Souichi, Toguchida, Junya, Matsuda, Shuichi, and Takita, Junko

Published
2023
Full Text
View/download PDF

41. PAX5 alterations in an infant case of KMT2A ‐rearranged leukemia with lineage switch

Author

Nakajima, Koji, primary, Kubota, Hirohito, additional, Kato, Itaru, additional, Isobe, Kiyotaka, additional, Ueno, Hiroo, additional, Kozuki, Kagehiro, additional, Tanaka, Kuniaki, additional, Kawabata, Naoko, additional, Mikami, Takashi, additional, Tamefusa, Kosuke, additional, Nishiuchi, Ritsuo, additional, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

42. Use of Cabozantinib to Treat MET-amplified Pediatric Colorectal Cancer

Author

Fukui, Sadahiro, primary, Umeda, Katsutsugu, additional, Kubota, Hirohito, additional, Iwai, Atsushi, additional, Akazawa, Ryo, additional, Isobe, Kiyotaka, additional, Tanaka, Kuniaki, additional, Kouzuki, Kagehiro, additional, Kawabata, Naoko, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Hiramatsu, Hidefumi, additional, Itatani, Yoshiro, additional, Funakoshi, Taro, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

43. Chimeric antigen receptor T‐cell therapy for a patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia and leukoencephalopathy who relapsed after bone marrow transplantation

Author

Kawabata, Naoko, primary, Hiramatsu, Hidefumi, additional, Mikami, Takashi, additional, Akazawa, Ryo, additional, Tanaka, Kuniaki, additional, Kouzuki, Kagehiro, additional, Kubota, Hirohito, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Umeda, Katsutsugu, additional, Hirate, Tomoaki, additional, Kanda, Kaori, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

44. Inotuzumab ozogamicin is an effective treatment for CD22-positive acute undifferentiated leukemia: A case report

Author

Akazawa, Ryo, primary, Kato, Itaru, additional, Kubota, Hirohito, additional, Isobe, Kiyotaka, additional, Masuno, Hiroaki, additional, Mikami, Masamitsu, additional, Shiota, Mitsutaka, additional, Kozuki, Kagehiro, additional, Kawabata, Naoko, additional, Tanaka, Kuniaki, additional, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Adachi, Souichi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

45. Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach

Author

Umeda, Katsutsugu, primary, Taura, Kojiro, additional, Kato, Itaru, additional, Saida, Satoshi, additional, Hiramatsu, Hidefumi, additional, Shimizu, Hironori, additional, Nakamoto, Yuji, additional, Uto, Megumi, additional, Mizowaki, Takashi, additional, Sakamoto, Akio, additional, Adachi, Souichi, additional, Okamoto, Takeshi, additional, and Takita, Junko, additional

Published
2022
Full Text
View/download PDF

46. Immature teratoma of the ovary associated with Cowden syndrome

Author

Kouzuki, Kagehiro, primary, Umeda, Katsutsugu, additional, Kawasaki, Hidenori, additional, Isobe, Kiyotaka, additional, Akazawa, Ryo, additional, Tasaka, Keiji, additional, Tanaka, Kuniaki, additional, Kubota, Hirohito, additional, Saida, Satoshi, additional, Kato, Itaru, additional, Hiramatsu, Hidefumi, additional, Sonoda, Mari, additional, Okamoto, Tatsuya, additional, Ogawa, Eri, additional, Kishida, Kenji, additional, and Takita, Junko, additional

Published
2021
Full Text
View/download PDF

49. Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia

Author

Mikami, Takashi, primary, Kato, Itaru, additional, Wing, James Badger, additional, Ueno, Hiroo, additional, Tasaka, Keiji, additional, Tanaka, Kuniaki, additional, Kubota, Hirohito, additional, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Isobe, Tomoya, additional, Hiwatari, Mitsuteru, additional, Okada, Ai, additional, Chiba, Kenichi, additional, Shiraishi, Yuichi, additional, Tanaka, Hiroko, additional, Miyano, Satoru, additional, Arakawa, Yuki, additional, Oshima, Koichi, additional, Koh, Katsuyoshi, additional, Adachi, Souichi, additional, Iwaisako, Keiko, additional, Ogawa, Seishi, additional, Sakaguchi, Shimon, additional, and Takita, Junko, additional

Published
2021
Full Text
View/download PDF

50. Mass Cytometric Analysis Revealed Dynamic Alteration of the Tumor Immune Environment in Bone Marrow from Children with Recurrent B Cell Precursor Acute Lymphoblastic Leukemia

Author

Mikami, Takashi, primary, Kato, Itaru, additional, Wing, James Badger, additional, Ueno, Hiroo, additional, Tasaka, Keiji, additional, Tanaka, Kuniaki, additional, Kubota, Hirohito, additional, Saida, Satoshi, additional, Umeda, Katsutsugu, additional, Hiramatsu, Hidefumi, additional, Isobe, Tomoya, additional, Okada, Ai, additional, Chiba, Kenichi, additional, Shiraishi, Yuichi, additional, Tanaka, Hiroko, additional, Miyano, Satoru, additional, Adachi, Soichi, additional, Iwaisako, Keiko, additional, Ogawa, Seishi, additional, Sakaguchi, Shimon, additional, and Takita, Junko, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results